Aspen Aerogels, Inc. (NYSE:ASPN) Given Average Rating of “Buy” by Analysts

Aspen Aerogels, Inc. (NYSE:ASPN) has received a consensus recommendation of “Buy” from the ten analysts that are covering the company, Marketbeat reports. Nine equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $28.70.

Several analysts have recently issued reports on ASPN shares. Barclays lowered their price objective on shares of Aspen Aerogels from $27.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Roth Mkm cut their price objective on Aspen Aerogels from $36.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, November 8th. StockNews.com raised Aspen Aerogels to a “sell” rating in a research note on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Aspen Aerogels in a research report on Wednesday, October 16th. Finally, TD Cowen raised their price target on shares of Aspen Aerogels from $36.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, August 20th.

Insider Buying and Selling at Aspen Aerogels

In related news, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $30.03, for a total value of $1,902,550.65. Following the sale, the chief executive officer now directly owns 483,640 shares of the company’s stock, valued at $14,523,709.20. This represents a 11.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Aspen Aerogels

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Aspen Aerogels by 5.1% during the 1st quarter. Vanguard Group Inc. now owns 3,619,702 shares of the construction company’s stock valued at $63,707,000 after buying an additional 175,906 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Aspen Aerogels by 15.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,580 shares of the construction company’s stock worth $257,000 after buying an additional 1,938 shares during the last quarter. California State Teachers Retirement System lifted its stake in Aspen Aerogels by 8.6% in the first quarter. California State Teachers Retirement System now owns 60,039 shares of the construction company’s stock valued at $1,057,000 after buying an additional 4,734 shares during the last quarter. Comerica Bank acquired a new position in shares of Aspen Aerogels during the first quarter valued at $1,992,000. Finally, Virtu Financial LLC bought a new stake in Aspen Aerogels in the 1st quarter valued at about $246,000. Institutional investors own 97.64% of the company’s stock.

Aspen Aerogels Price Performance

ASPN opened at $13.49 on Friday. Aspen Aerogels has a 1 year low of $10.75 and a 1 year high of $33.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.48 and a current ratio of 2.93. The company’s 50 day simple moving average is $18.91 and its 200 day simple moving average is $23.59. The stock has a market capitalization of $1.11 billion, a PE ratio of 1,350.35 and a beta of 2.11.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.